Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Aug
14
Today In Oncology
TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
Advanced Gastric or GEJ Cancer First-Line Disitamab Vedotin, Tislelizumab, and S-1
Proton Pump Inhibitor, Antibiotic Exposure Linked to Inferior Durvalumab Outcomes in Unresectable Stage III NSCLC
Does ctDNA-Guided Surveillance After Curative-Intent Surgery Benefit Outcomes in Cases of Recurrent Colorectal Cancer
Darolutamide Plus Goserelin in AR-Positive Salivary Gland Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo